Michael Chambers - Aug 16, 2024 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Ryan Brown as Attorney-in-Fact for Michael Chambers
Stock symbol
SRPT
Transactions as of
Aug 16, 2024
Transactions value $
$4,955,728
Form type
4
Date filed
8/20/2024, 08:00 AM
Previous filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $1.74M +13.1K +5.31% $133.07 260K Aug 16, 2024 By Revocable Trust F1
transaction SRPT Common Stock Purchase $2.45M +18.3K +7.03% $134.06 278K Aug 16, 2024 By Revocable Trust F2
transaction SRPT Common Stock Purchase $761K +5.65K +2.03% $134.66 284K Aug 16, 2024 By Revocable Trust F3
holding SRPT Common Stock 8.28K Aug 16, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.